Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent RNAi- and microRNA-Related Patents and Patent Applications: Aug 25, 2011

Premium

Title: Methods and Compositions Involving microRNA

Patent Number: 8,003,320

Filed: Aug. 11, 2007

Lead Inventor: David Brown, Asuragen

The invention, the patent's abstract states, “concerns methods and compositions for isolating, enriching, and/or labeling miRNA molecules and for preparing and using arrays or other detection techniques for miRNA analysis. Moreover, the … invention concerns methods and compositions for generating miRNA profiles and employing such profiles for therapeutic, diagnostic, and prognostic applications.”


Title: AIMP2-DX2 Gene and siRNA Targeting AIMP2-DX2

Patent Number: 8,003,780

Filed: Oct. 22, 2008

Lead Inventor: Sunghoon Kim, Neomics

The invention, the patent's abstract states, “relates to a variant of AIMP2 lacking exon 2 gene, named ... AIMP2-DX2 gene, which is specifically expressed in cancer cells. The AIMP2-DX2 gene and siRNA targeting AIMP2-DX2 can be successfully used in the development of diagnosis and treatment of cancer.”


Title: Composition for Suppressing the Expression of Fucosyltransferase

Patent Number: 8,003,781

Filed: Jan. 6, 2009

Lead Inventor: Akihiro Kondo, Osaka University (Takara Bio)

The invention comprises a “means for reducing the expression amount of a FUT8 gene, reducing the expression amount of a FUT8 protein, and/or reducing the expression amount of a product produced by the action of FUT8,” the patent's abstract states.

The patent specifically claims the use of dsRNA to inhibit FUT8.


Title: Lipids, Lipid Compositions, and Methods of Using Them

Application Number: 20110200582

Filed: Dec. 21, 2010

Lead Inventor: Jeremy Baryza, Novartis

The invention comprises “formulation and optimization protocols for delivery of therapeutically effective amounts of biologically active agents to liver, tumors, and/or other cells or tissues,” the patent application's abstract states. “The invention also relates to compositions and uses for stealth lipids … [as well as] processes for making such compounds, compositions, and formulations, plus methods and uses of such compounds, compositions, and formulations to deliver biologically active agents to cells and/or tissues.”


Title: Oligonucleotide Detection Method

Application Number: 20110201006

Filed: Oct. 6, 2009

Lead Inventor: Ingo Roehl, Roche

“The invention relates to a method for the detection of oligonucleotides using anion exchange high performance liquid chromatography,” the patent application's abstract states. “Fluorescently labeled peptide nucleic acid oligomers, complementary to the oligonucleotide are hybridized to the oligonucleotides. Anion exchange high performance liquid chromatography is then performed and the hybridized moieties detected and quantitated. The invention also relates to a method for the simultaneous detection of both strands of an oligonucleotide in parallel from one sample, and a kit for use in qualitative and quantitative detection of one or two strands of an oligonucleotide.”


Title: System for Synergetic Expression of Multiple Small Functional RNA Elements

Application Number: 20110201103

Filed: Aug. 7, 2009

Lead Inventor: Gangning Liang, University of Southern California

The invention relates to microRNAs, the patent application's abstract states. “More specifically, the invention relates to expression vectors comprising multiple miRNA families and clusters capable of targeting multiple oncogenic pathways.”


Title: Compositions and Methods for the Detection of Small RNAs

Application Number: 20110201515

Filed: Feb. 11, 2011

Lead Inventor: Philippa Webster, NanoString

“The invention provides compositions and methods for the detection of small RNA molecules in a multiplexed reaction,” according to the patent application's abstract. “The assays and kits described herein are applicable for the identification, diagnosing, and monitoring of disorders including, but not limited to cancer, developmental and degenerative disease, neurological disorders, and stem cell disorders.”


Title: Compositions and Methods for Silencing Ebola Virus Gene Expression

Application Number: 20110201667

Filed: July 10, 2010

Lead Inventor: Thomas Geisbert, Protiva Biotherapeutics (Tekmira Pharmaceuticals)

The invention provides “compositions comprising therapeutic nucleic acids that target Ebola virus gene expression and methods of using such compositions to silence [Ebola virus] gene expression,” the patent application's abstract states. “More particularly, the invention provides unmodified and chemically modified interfering RNA which silence [Ebola virus] gene expression and methods of use thereof, e.g., for preventing or treating [Ebola virus] infections caused by one or more [Ebola virus] species such as Zaire [Ebola virus]. The invention also provides serum-stable nucleic acid-lipid particles comprising one or more interfering RNA molecules, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. Methods of silencing [Ebola virus] gene expression by administering one or more interfering RNA molecules to a mammalian subject are also provided.”


Title: Methods and Compositions for the Diagnosis and Treatment of Cancer

Application Number: 20110201669

Filed: July 20, 2009

Inventor: Jian Cao, State University of New York

The invention relates to the “diagnosis and treatment of cancer, and in particular, breast cancer,” the patent application's abstract states. “Specifically, in some embodiments the invention relates to methods of diagnosing cancer ... using an antibody specific for a gene product that localizes selectively to the endoplasmic reticulum of the cancer cells. In some embodiments, the invention relates to methods of treating cancer ... by administering a composition comprising an RNA interference sequence characterized by an ability to inhibit an mRNA molecule, which mRNA molecule is encoded by the C43 gene.

“The invention additionally relates to methods for detecting cancer cells by detecting reduced methylation of the C43 promoter, and methods for reducing cancer metastasis by using demethylation inhibitors that result in increased methylation of the C43 promoter,” the abstract adds. “The invention additionally relates to an in vitro 3-dimensional assay for detecting migrating cells, identifying test agents and/or nucleotide sequences that alter cell migration.”


Title: Oligoribonucleotides and Methods of Use Thereof for Treatment of Fibrotic Conditions and Other Diseases

Application Number: 20110201670

Filed: April 22, 2011

Lead Inventor: Orna Mor, Quark Pharmaceuticals

“The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human TGaseII gene at the post-transcriptional level,” according to the patent application's abstract. “The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. “

“The ... invention also contemplates a method of treating a patient suffering from a fibrotic disease such as pulmonary, kidney and liver fibrosis, or ocular scarring comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient,” it adds. “The invention also relates to treatment of fibrotic and other diseases by use of antibodies to TGaseII polypeptide.”


Title: Compositions and Methods for Inhibiting Expression of a Gene from the Ebola Virus

Application Number: 20110201671

Filed: April 25, 2011

Lead Inventor: Sina Bavari, Alnylam Pharmaceuticals

“The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of a gene from the Ebola virus,” the patent application's abstract states.


Title: Therapeutic Compositions

Application Number: 20110201798

Filed: July 16, 2010

Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals

The invention, the patent application's abstract states, “relates to therapeutic siRNA agents and methods of making and using the agents.”


Title: Assays, Methods, and Kits for Measuring Response to Therapy and Predicting Clinical Outcome in Patients with B-Cell Lymphoma

Application Number: 20110201008

Filed: Dec. 1, 2010

Lead Inventor: Izidore Lossos, University of Miami

“Assays, methods, and kits for predicting survival outcome in a subject having diffuse large B-cell lymphoma and for measuring a subject's response to DLBCL therapy involve specific miRNAs that are prognostic biomarkers for prediction of outcome of DLBCL patients,” the patent application's abstract states. “Expression of miRNAs miR-18a, miR-181a, and miR-222 is associated with response to therapy and outcome of patients with DLBCL. Measurement of these miRs can be used to identify patients' outcomes in the clinic and allow tailoring of patient-specific therapy.”

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.